{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:05:34Z","timestamp":1761491134703,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.nmd.2020.12.001","type":"journal-article","created":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T09:44:13Z","timestamp":1607247853000},"page":"91-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effect of long term enzyme replacement therapy in late onset Pompe disease: A single-centre experience"],"prefix":"10.1016","volume":"31","author":[{"given":"George K.","family":"Papadimas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoforos","family":"Anagnostopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Xirou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Michelakakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerasimos","family":"Terzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Mavridou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelia","family":"Kararizou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantinos","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2020.12.001_bib0001","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh384","article-title":"Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients","volume":"128","author":"Hagemans","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2020.12.001_bib0002","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00415-005-0922-9","article-title":"The natural course of non\u2013classic Pompe's disease; a review of 225 published cases","volume":"252","author":"Winkel","year":"2005","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2020.12.001_bib0003","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"Infantile-onset Pompe disease natural history study group A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.nmd.2020.12.001_bib0004","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1750-1172-7-88","article-title":"Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study","volume":"7","author":"van der Beek","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2020.12.001_bib0005","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2020.12.001_bib0006","first-page":"85","article-title":"Familial adult-onset Pompe disease associated with unusual clinical and histological features","volume":"32","author":"Maggi","year":"2013","journal-title":"Acta Myol"},{"key":"10.1016\/j.nmd.2020.12.001_bib0007","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s00415-015-7664-0","article-title":"Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment","volume":"262","author":"Montagnese","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2020.12.001_bib0008","series-title":"Advances in diagnosis and management of glycogenosis II","first-page":"39","article-title":"Juvenile and adult forms of type II glycogenosis: clinical aspects","author":"Lamperti","year":"2013"},{"key":"10.1016\/j.nmd.2020.12.001_bib0009","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2174\/1566524014666141010131649","article-title":"Late-onset glycogen storage disease type 2","volume":"14","author":"Filosto","year":"2014","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.nmd.2020.12.001_bib0010","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet Med"},{"key":"10.1016\/j.nmd.2020.12.001_bib0011","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"Van der Ploeg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2020.12.001_bib0012","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10545-012-9451-8","article-title":"36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy","volume":"35","author":"Regnery","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nmd.2020.12.001_bib0013","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","author":"Strothotte","year":"2010","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2020.12.001_bib0014","doi-asserted-by":"crossref","unstructured":"Gungor D., Kruijshaar M.E., Plug I., D'Agostino R.B., Hagemans M.L., van Doorn P.A., et al. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis 2013:8:49.","DOI":"10.1186\/1750-1172-8-49"},{"key":"10.1016\/j.nmd.2020.12.001_bib0015","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2020.12.001_bib0016","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1212\/WNL.0000000000008441","article-title":"Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease","volume":"93","author":"Harlaar","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2020.12.001_bib0017","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1164\/rccm.166.4.518","article-title":"ATS\/ERS statement on respiratory muscle testing","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.nmd.2020.12.001_bib0018","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.nmd.2015.03.010","article-title":"Role of the cardio-pulmonary exercise test and six-minute walking test in the evaluation of exercise performance in patients with late-onset Pompe disease","volume":"25","author":"Crescimanno","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2020.12.001_bib0019","series-title":"Statistical models in s","first-page":"309","article-title":"Local regression models","author":"Cleveland","year":"2017"},{"key":"10.1016\/j.nmd.2020.12.001_bib0020","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0167-7152(96)00128-9","article-title":"Unifying the derivations for the Akaike and corrected Akaike information criteria","volume":"33","author":"Cavanaugh","year":"1997","journal-title":"Stat Probab Lett"},{"key":"10.1016\/j.nmd.2020.12.001_bib0021","first-page":"1","article-title":"fANCOVA: nonparametric Analysis of Covariance","volume":"0","author":"Wang","year":"2010","journal-title":"R Package version"},{"key":"10.1016\/j.nmd.2020.12.001_bib0022","first-page":"1261","article-title":"bootstrap and other resampling methods in regression analysis (with discussion)","volume":"14","author":"Jackknife","year":"1986","journal-title":"Ann Stat"},{"key":"10.1016\/j.nmd.2020.12.001_bib0023","first-page":"497","article-title":"Clinical guidelines for late-onset Pompe disease","volume":"54","author":"Barba-Romero","year":"2012","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nmd.2020.12.001_bib0024","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clineuro.2010.12.005","article-title":"Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy","volume":"113","author":"Papadimas","year":"2011","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.nmd.2020.12.001_bib0025","doi-asserted-by":"crossref","unstructured":"Papadopoulos C., Papadimas G.K., Spengos K., Manta P. Pretreatment antibodies against acid a-glucosidase in a patient with late-onset Pompe disease. Muscle Nerve 2012:45:452.","DOI":"10.1002\/mus.22304"},{"key":"10.1016\/j.nmd.2020.12.001_bib0026","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.nmd.2020.12.001_bib0027","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","article-title":"Open-label extension study following the late-onset treatment study (LOTS) of alglucosidase alfa","volume":"107","author":"van der Ploeg","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2020.12.001_bib0028","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","article-title":"Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review","volume":"260","author":"Toscano","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2020.12.001_bib0029","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.12272","article-title":"Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: prospective analysis from the French Pompe Registry","author":"Semplicini","year":"2020","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nmd.2020.12.001_bib0030","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/ene.13285","article-title":"European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience","volume":"24","author":"van der Ploeg","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2020.12.001_bib0031","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.nmd.2019.11.007","article-title":"Discontinuation of enzyme replacement therapy in adults with Pompe disease: evaluating the European Pompe consortium stop criteria","volume":"30","author":"van Kooten","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2020.12.001_bib0032","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fnagi.2014.00177","article-title":"Pompe disease: from pathophysiology to therapy and back again","volume":"6","author":"Lim","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.nmd.2020.12.001_bib0033","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2018.04.025","article-title":"Therapeutic benefit of autophagy modulation in Pompe disease","volume":"26","author":"Lim","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.nmd.2020.12.001_bib0034","doi-asserted-by":"crossref","first-page":"313","DOI":"10.21037\/atm.2018.06.52","article-title":"Pompe disease: how to solve many problems with one solution","volume":"6","author":"Puertollano","year":"2018","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.nmd.2020.12.001_bib0035","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2016.12.004","article-title":"The emerging phenotype of late-onset Pompe disease: a systematic literature review","volume":"120","author":"Chan","year":"2017","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2020.12.001_bib0036","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/ene.13835","article-title":"Central nervous system involvement in late-onset Pompe disease: clues from neuroimaging and neuropsychological analysis","volume":"26","author":"Musumeci","year":"2019","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2020.12.001_bib0037","first-page":"479","article-title":"A systematic review of the health economics of Pompe disease","volume":"3","author":"Schoser","year":"2019","journal-title":"Pharmacoecon"},{"key":"10.1016\/j.nmd.2020.12.001_bib0038","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1007\/s00415-018-9065-7","article-title":"36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe registry","volume":"265","author":"Scheidegger","year":"2018","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2020.12.001_bib0039","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ymgme.2017.06.007","article-title":"Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme(R)) in 12 patients with advanced late-onset Pompe disease","volume":"122","author":"Papadopoulos","year":"2017","journal-title":"Mol Genet Metab"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896620306957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896620306957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:10:44Z","timestamp":1760775044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896620306957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0960896620306957"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2020.12.001","relation":{},"ISSN":["0960-8966"],"issn-type":[{"type":"print","value":"0960-8966"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of long term enzyme replacement therapy in late onset Pompe disease: A single-centre experience","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2020.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}